GENE THERAPY OF X-LINKED CHRONIC GRANULOMATOUS DISEASE

X连锁慢性肉芽肿性疾病的基因治疗

基本信息

项目摘要

X-linked chronic granulomatous disease (X-CGD) arises from defects in the gene encoding gp91/phox, a subunit of a phagocyte-specific cytochrome b that is essential for respiratory burst oxidase function. Affected patients lack a major antimicrobial pathway and develop recurrent, severe infections beginning in early childhood. The objective of the proposed research is to establish an experimental basis for gene replacement therapy of X-CGD using replication-defective retroviruses for expression of gp91/phox. The central hypothesis underlying this objective is that retroviral-mediated gene transfer of gp91/phox cDNA into X-CGD hematopoietic stem cells will restore respiratory burst activity in mature phagocytic leukocytes and correct the defect in host defense. In the proposed research plan, retroviral vectors containing the gp91 cDNA will be prepared utilizing designs previously shown by others to confer long-term expression in vivo of transferred gene sequences. These vectors will be tested for their ability to confer functional expression of gp91/phox in human X-CGD hematopoietic stem and progenitor cells. In addition to bone marrow cells, hematopoietic precursors isolated from peripheral blood will be evaluated as targets for gene transfer and also as candidates of ex vivo expansion prior to transduction. Protocols developed for efficient transduction of marrow cells will be modified, if necessary, for peripheral blood cell targets. Gene transfer and expression will be first investigated using in vitro clonogenic assays of stem and progenitor cells. A human- sheep xenograft model will be used to assess transduced target cells for long-term, in vivo, bone marrow populating capabilities and the functional expression of recombinant gp91/phox in mature phagocytic leukocytes. The work outlined in this subproject should aid in the development of clinical protocols using retroviral-mediated gene transfer as a therapeutic strategy in X- CGD and other single-gene defects of hematopoietic stem cells. More broadly, these studies should add to knowledge of how to introduce specific genetic modifications into hematopoietic stem cells while maintaining self-renewal and multipotentiality.
x -连锁慢性肉芽肿病(X-CGD)是由肝细胞的缺陷引起的

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mary C Dinauer其他文献

Mary C Dinauer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mary C Dinauer', 18)}}的其他基金

SELECTIVE DELETION OF NEUTROPHIL NADPH OXIDASE AND INNATE RESPONSES TO ASPERGILLUS FUMIGATUS
中性粒细胞 NADPH 氧化酶的选择性缺失和对烟曲霉的先天反应
  • 批准号:
    9368526
  • 财政年份:
    2017
  • 资助金额:
    $ 12.08万
  • 项目类别:
GENE THERAPY OF X-LINKED CHRONIC GRANULOMATOUS DISEASE
X连锁慢性肉芽肿性疾病的基因治疗
  • 批准号:
    7458723
  • 财政年份:
    2007
  • 资助金额:
    $ 12.08万
  • 项目类别:
GENE THERAPY OF X-LINKED CHRONIC GRANULOMATOUS DISEASE
X连锁慢性肉芽肿性疾病的基因治疗
  • 批准号:
    7440956
  • 财政年份:
    2006
  • 资助金额:
    $ 12.08万
  • 项目类别:
2005 Phagocytes Gordon Conference
2005年吞噬细胞戈登会议
  • 批准号:
    7001142
  • 财政年份:
    2005
  • 资助金额:
    $ 12.08万
  • 项目类别:
Administrative
行政的
  • 批准号:
    7414661
  • 财政年份:
    2005
  • 资助金额:
    $ 12.08万
  • 项目类别:
GENE THERAPY OF X-LINKED CHRONIC GRANULOMATOUS DISEASE
X连锁慢性肉芽肿性疾病的基因治疗
  • 批准号:
    7089588
  • 财政年份:
    2005
  • 资助金额:
    $ 12.08万
  • 项目类别:
Core C- Administrative Core
核心 C- 行政核心
  • 批准号:
    6987703
  • 财政年份:
    2004
  • 资助金额:
    $ 12.08万
  • 项目类别:
GENE THERAPY OF X-LINKED CHRONIC GRANULOMATOUS DISEASE
X连锁慢性肉芽肿性疾病的基因治疗
  • 批准号:
    6879596
  • 财政年份:
    2004
  • 资助金额:
    $ 12.08万
  • 项目类别:
Regulation of phagocyte function by Rac2
Rac2 对吞噬细胞功能的调节
  • 批准号:
    6595706
  • 财政年份:
    2002
  • 资助金额:
    $ 12.08万
  • 项目类别:
GENE THERAPY OF X-LINKED CHRONIC GRANULOMATOUS DISEASE
X连锁慢性肉芽肿性疾病的基因治疗
  • 批准号:
    6110406
  • 财政年份:
    1998
  • 资助金额:
    $ 12.08万
  • 项目类别:

相似国自然基金

基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
  • 批准号:
    61602201
  • 批准年份:
    2016
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
  • 批准号:
    81170309
  • 批准年份:
    2011
  • 资助金额:
    50.0 万元
  • 项目类别:
    面上项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
  • 批准号:
    30672394
  • 批准年份:
    2006
  • 资助金额:
    30.0 万元
  • 项目类别:
    面上项目

相似海外基金

酸化ストレス応答アポトーシス誘導蛋白のUCに対する新規Biomarker探索と治療への展開
寻找治疗 UC 的氧化应激反应性凋亡诱导蛋白的新生物标志物并开发治疗方法
  • 批准号:
    24K11919
  • 财政年份:
    2024
  • 资助金额:
    $ 12.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
肝内胆管癌新規Biomarkerの同定及び癌周囲間質を標的とした新規治療開発
鉴定肝内胆管癌的新型生物标志物并开发针对癌周基质的新疗法
  • 批准号:
    24K19350
  • 财政年份:
    2024
  • 资助金额:
    $ 12.08万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
収縮能が保たれた心不全の機械学習分類とmicroRNAなどのbiomarkerの探索
机器学习对具有保留收缩性的心力衰竭进行分类并搜索 microRNA 等生物标志物
  • 批准号:
    24K19007
  • 财政年份:
    2024
  • 资助金额:
    $ 12.08万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Development of a predictive biomarker for Parkinson's disease
帕金森病预测生物标志物的开发
  • 批准号:
    MR/Y019415/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.08万
  • 项目类别:
    Research Grant
Sleep and circadian dysfunction in ageing and neurodegeneration: a life course and biomarker study of the British 1946 birth cohort.
衰老和神经退行性疾病中的睡眠和昼夜节律功能障碍:对英国 1946 年出生队列的生命历程和生物标志物研究。
  • 批准号:
    MR/Y009452/1
  • 财政年份:
    2024
  • 资助金额:
    $ 12.08万
  • 项目类别:
    Fellowship
Biomarker-Based Platform for Early Diagnosis of Chronic Liver Disease to Enable Personalized Therapy (LIVERAIM)
基于生物标志物的慢性肝病早期诊断平台,以实现个性化治疗(LIVERAIM)
  • 批准号:
    10087822
  • 财政年份:
    2024
  • 资助金额:
    $ 12.08万
  • 项目类别:
    EU-Funded
Enhanced stratification of COPD patients via integration of a digitally enabled biomarker Point-of-Care test within a Remote Patient Monitoring tool
通过在远程患者监测工具中集成数字化生物标志物即时检测,增强 COPD 患者的分层
  • 批准号:
    10098600
  • 财政年份:
    2024
  • 资助金额:
    $ 12.08万
  • 项目类别:
    Collaborative R&D
QuBIE: Quantitative Biomarker Identification for Non-Endoscopic Prediction and Monitoring of Treatment Response in Eosinophilic Oesophagitis
QuBIE:用于非内镜预测和监测嗜酸性食管炎治疗反应的定量生物标志物鉴定
  • 批准号:
    10083253
  • 财政年份:
    2024
  • 资助金额:
    $ 12.08万
  • 项目类别:
    Collaborative R&D
膵癌腫瘍内線維化に着目した術前化学療法効果予測に関する画像biomarkerの確立
建立预测胰腺癌瘤内纤维化术前化疗效果的影像生物标志物
  • 批准号:
    24K18824
  • 财政年份:
    2024
  • 资助金额:
    $ 12.08万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Multi-modal non-invasive biomarker screening for high-risk undiagnosed liver disease
针对高危未确诊肝病的多模式非侵入性生物标志物筛查
  • 批准号:
    10073169
  • 财政年份:
    2023
  • 资助金额:
    $ 12.08万
  • 项目类别:
    Collaborative R&D
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了